Neuromuscular Disease Therapeutics Market to grow by USD 13.73 Billion (2025-2029)

The global neuromuscular disease therapeutics market size is estimated to grow by USD 13.73 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 14.6% during the forecast period. Novel approvals for neuromuscular disease therapeutics is driving market growth, with a trend towards technological advances in neuromuscular disease therapy. However, high cost of neuromuscular disease therapeutics on patients poses a challenge. Key market players include AbbVie Inc., Aquestive Therapeutics Inc, argenx SE, AstraZeneca Plc, Biogen Inc., CuraVac. Hoffmann La Roche Ltd., Grifols SA, Merck and Co. Inc., Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Roivant Sciences Ltd., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd..

Health Technology Insights: Estonia Showcases Digital Health Leadership at Arab Health 2025 

Health Technology Insights: Allergan Aesthetics launches new AA Signature Program at IMCAS 2025

Market Driver

Neuromuscular Disease Therapeutics Market: Trends and Insights The Neuromuscular Disease Therapeutics Market is witnessing significant growth due to the increasing focus on safety and efficacy in nerve impulse transmission. Orthopedics and critical care settings are key areas of application, with a growing need for optimal muscle relaxation in medical settings. The pipeline analysis reveals a strong focus on nerve impulses, motor neurons, and the neuromuscular junction, with ongoing research in oncology, cardiovascular disease, paralysis, and epilepsy. The geriatric population and surgical procedures in surgical settings are major patient epidemiology drivers. Complications from surgery and surgical sites are a concern, and the regulatory framework is crucial for ensuring surgical outcomes. Research and development is a top priority, with collaborations between healthcare infrastructure, expert analysis, and media coverage driving innovation. Drug development for chronic diseases like neuromuscular diseases, multiple sclerosis, and epilepsy is a key trend. Pharmaceuticals, medical technology, and personalized medicine are all playing a role in improving quality of life for patients. Government funding and support for rare diseases and immunotherapy are also driving growth in this market. Unhealthy lifestyles and unmet medical needs are creating opportunities for topical applications and intravenous administration. The market for neuromuscular disease therapeutics is expected to continue growing, driven by disease awareness, research collaborations, and advancements in medical technology. 

Health Technology Insights: TARA Mind Launches Free Provider Training to Advance Clinicians’ Expertise

The neuromuscular disease therapeutics market is experiencing significant growth due to technological advancements driving research and development of novel therapies. Vendors focus on regenerative treatments, such as antisense therapy using oligonucleotides, gene therapies, and cell therapies, to address the inadequacy of non-disease-modifying drugs. However, large-scale manufacturing and development costs pose a challenge for gene therapies. Companies are investing in these innovative treatments to cater to the unmet medical needs in neuromuscular diseases. 

Health Technology Insights: Change to the Roche Enlarged Corporate Executive Committee

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – prnewswire